Fungal Meningitis in the UK Symptoms Diagnosis and Treatment

Fungal meningitis is uncommon in the UK, but the cases that do occur are often high stakes. Diagnosis may be delayed because presentation overlaps with tuberculosis, viral encephalitis, neurosarcoidosis, malignancy, and partially treated bacterial meningitis. The clinical course can be subacute, CSF microscopy may be unrevealing, and early imaging may not exclude CNS infection.

From a UK microbiology perspective, the key is to identify the syndrome early, test the right specimens, and involve microbiology, infectious diseases, neurology, neuroradiology, neurosurgery, HIV medicine, haematology, or transplant teams as soon as the risk profile becomes clear.

This article is for clinical education and should not replace local NHS guidance, specialist microbiology advice, or national recommendations.

Early CSF sampling is central to diagnosis when fungal meningitis is suspected.

Why fungal meningitis is easy to miss in the UK

Fungal meningitis is rare compared with viral and bacterial meningitis, but rarity is part of the problem. Many UK clinicians may see very few cases in training. The most frequent clinically important causes in UK practice relate to immunosuppression, travel, transplantation, haematological disease, neurosurgery, or advanced HIV.

The differential is broad. In practice, it includes Cryptococcus, Histoplasma, Coccidioides, Aspergillus, Mucormycosis, Candida, and occasional endemic or mould infections acquired abroad.

A useful mental model is to split cases into four groups:

Clinical setting	Likely pathogens to consider	UK clues
Advanced HIV or profound T-cell dysfunction	Cryptococcus neoformans, Histoplasma capsulatum	New HIV diagnosis, low CD4 count, travel, weight loss
Transplant, haematology, prolonged steroids, biologics	Aspergillus, Mucorales, Cryptococcus, Candida	Neutropenia, GVHD, calcineurin inhibitors, azoles, sinus disease
Neurosurgery, shunts, drains, intrathecal devices	Candida, moulds, occasionally environmental fungi	Device infection, persistent CSF pleocytosis, negative bacterial cultures
Relevant travel or migration	Coccidioides, Histoplasma, Blastomyces	Residence or travel in endemic regions, pulmonary illness, eosinophilia

Cryptococcal meningitis remains the most recognised form worldwide. The WHO has issued guidance for cryptococcal disease in people living with HIV, and UK services follow specialist pathways based on national and international evidence. Imported endemic mycoses are less common, but they matter because diagnosis often depends on asking about travel, work, caves, bird or bat guano, soil exposure, and residence outside the UK.

Symptoms and clinical patterns that should raise suspicion

Symptoms are often less abrupt than in meningococcal disease. The presentation may evolve over days to weeks, and fever can be absent, particularly in heavily immunosuppressed patients.

Common features include:

• Headache, often persistent and progressive

• Fever, sweats, malaise, or weight loss

• Nausea and vomiting

• Photophobia or neck stiffness, which may be mild or absent

• Confusion, drowsiness, altered behaviour, or cognitive slowing

• Cranial nerve palsies, diplopia, hearing symptoms, or visual disturbance

• Seizures or focal neurological signs

• Features of raised intracranial pressure

  
  

In cryptococcal meningitis, raised intracranial pressure is clinically important. Patients may present with severe headache, vomiting, papilloedema, sixth nerve palsy, or reduced consciousness. CSF opening pressure should be measured whenever safe to do so. Repeated therapeutic lumbar puncture can be as important as antifungal therapy in selected patients, in line with specialist guidance.

Coccidioidal meningitis, when imported, is classically chronic and can cause basilar meningitis, hydrocephalus, vasculitic infarcts, and cranial neuropathies. Histoplasma meningitis can mimic tuberculosis or malignancy, with lymphocytic CSF and systemic clues such as pulmonary disease, hepatosplenomegaly, adrenal involvement, or cytopenias.

Mould meningitis is different. Aspergillus CNS disease often reflects angioinvasion and dissemination, especially in neutropenia, haematological malignancy, transplant recipients, and corticosteroid exposure. It may present with stroke-like deficits, brain abscess, haemorrhage, seizures, or meningoencephalitis rather than a pure meningitic picture. Rhino-orbital-cerebral mucormycosis should be considered in patients with diabetes, ketoacidosis, haematological malignancy, iron overload, or profound immunosuppression, especially with sinus pain, orbital signs, black eschar, or rapidly progressive cranial neuropathy.

A normal early CT brain does not exclude fungal CNS infection. It mainly helps assess safety for lumbar puncture and identify complications such as hydrocephalus, infarction, abscess, or mass effect.

MRI helps define complications such as hydrocephalus, infarction, abscess, and basal meningitis.

Diagnostic approach in NHS practice

Diagnosis rests on combining clinical syndrome, host factors, imaging, CSF findings, mycology tests, and tissue diagnosis where needed. No single test covers all causes.

The first step is to identify the patient in whom fungal disease is plausible. Red flags include:

• Advanced or untreated HIV

• Solid organ or stem cell transplant

• Haematological malignancy

• Neutropenia

• Prolonged corticosteroids or other immunosuppressive agents

• Anti-TNF or other biologic therapy

• Diabetes with suspected mucormycosis

• Neurosurgical devices or recent CNS procedures

• Travel, migration, or occupational exposure relevant to endemic mycoses

  
  

CSF testing

When lumbar puncture is safe, send enough CSF. Low-volume CSF sampling is a common reason for missed diagnosis. In a suspected fungal meningitis case, the microbiology laboratory should be alerted so that CSF is processed for appropriate stains, cultures, and antigen or molecular tests.

Core CSF tests usually include:

Test	Why it matters
Opening pressure	Essential in suspected cryptococcal disease and hydrocephalus
Cell count and differential	Often lymphocytic, but neutrophilic or mixed patterns occur
Protein and glucose with paired serum glucose	Low glucose and high protein suggest chronic meningitis
Gram stain and bacterial culture	Bacterial disease must still be excluded
Fungal microscopy and culture	Culture allows species identification and susceptibility testing
Cryptococcal antigen	Rapid and sensitive for cryptococcal disease in CSF and serum
Mycobacterial tests	TB meningitis remains a key UK differential
Viral PCR where indicated	HSV, VZV, enterovirus, and others depending on syndrome
Cytology or flow cytometry	Consider malignancy in chronic meningitis
Broad-range PCR or metagenomics	Discuss with reference laboratories in selected difficult cases

Cryptococcal antigen testing is one of the most useful early tests. A positive CSF cryptococcal antigen in a compatible syndrome is highly supportive of diagnosis. Serum cryptococcal antigen can also help, especially when LP is delayed or CNS disease is suspected in advanced HIV.

CSF fungal culture remains important, but it can be slow. A negative early culture does not rule out disease. For moulds, CSF culture may be insensitive. Serum galactomannan, bronchoalveolar lavage galactomannan, fungal PCR from tissue, histopathology, and imaging may carry more diagnostic weight than CSF alone.

Blood, respiratory, and tissue samples

The CNS may be one site of disseminated infection. Do not restrict sampling to CSF.

Useful specimens can include:

• Blood cultures, including fungal cultures where locally available and indicated

• Serum cryptococcal antigen

• HIV test, if status is unknown or risk has changed

• CD4 count and HIV viral load in people with HIV

• Serum beta-D-glucan, interpreted cautiously

• Serum galactomannan for suspected invasive aspergillosis

• CT chest, abdomen, and pelvis when disseminated disease is possible

• Respiratory samples if pulmonary lesions are present

• Sinus, brain, skin, lymph node, bone marrow, or other tissue for histology and culture

  
  

For mucormycosis, tissue diagnosis is particularly important. Histology may show broad, ribbon-like, pauciseptate hyphae with angioinvasion. Culture helps identify the organism, but prior antifungals and tissue necrosis can reduce yield. If rhino-orbital-cerebral disease is suspected, urgent ENT and surgical input should not wait for a perfect microbiological result.

Imaging

MRI brain with contrast is usually more sensitive than CT for meningeal enhancement, infarcts, abscesses, ventriculitis, cranial nerve involvement, and basal meningitis. CT remains useful when MRI is unavailable or when rapid assessment for mass effect is needed before LP.

Imaging patterns can guide the differential:

• Basal meningeal enhancement suggests TB, cryptococcosis, coccidioidomycosis, histoplasmosis, or malignancy

• Multiple infarcts suggest vasculitis or angioinvasive mould disease

• Ring-enhancing lesions may indicate abscess, toxoplasmosis, TB, fungal infection, or malignancy

• Sinus and orbital invasion points towards mucormycosis or aspergillosis

• Hydrocephalus may complicate cryptococcal, TB, coccidioidal, or other chronic meningitides

  
  

Culture and microscopy remain important, even when antigen and molecular tests are available.

Treatment principles and organism-specific therapy

Treatment should start promptly once suspicion is strong, particularly in severely ill or immunocompromised patients. Choice of therapy depends on the likely pathogen, CNS penetration, host factors, drug toxicities, interactions, and whether source control is needed.

Specialist input is essential. Most UK hospitals manage these cases with consultant microbiology or infectious diseases advice, and complex mycology cases may involve regional mycology expertise or reference laboratory support.

Cryptococcal meningitis

For cryptococcal meningitis, induction therapy traditionally includes amphotericin B with flucytosine, followed by fluconazole consolidation and maintenance. Liposomal amphotericin B is commonly used in UK practice because it is less nephrotoxic than conventional amphotericin B, though renal toxicity, electrolyte wasting, anaemia, and infusion reactions still need close monitoring.

Key management points include:

• Measure and manage opening pressure

• Use flucytosine dosing guided by renal function and, where available, therapeutic drug monitoring

• Monitor renal function, full blood count, liver tests, potassium, and magnesium

• Avoid premature antiretroviral therapy in HIV-associated cryptococcal meningitis because of immune reconstitution inflammatory syndrome risk, following current HIV guidance

• Repeat CSF evaluation when clinically indicated and to assess sterilisation in selected cases

  
  

The timing of antiretroviral therapy should be agreed with HIV specialists. WHO and HIV guideline groups advise caution because early ART can worsen intracranial inflammation in cryptococcal meningitis.

Histoplasma meningitis

Histoplasma CNS disease usually requires prolonged therapy. Liposomal amphotericin B is commonly used for induction, followed by long-course itraconazole where the isolate and clinical context support it. Therapeutic drug monitoring matters because itraconazole absorption varies, and interactions are common. Antigen testing in urine, serum, and CSF may support diagnosis and follow-up, though availability and interpretation should be discussed with specialist laboratories.

Coccidioidal meningitis

Coccidioidal meningitis generally requires prolonged azole therapy, often fluconazole at higher doses than used for many Candida infections. Relapse risk is well recognised when therapy stops. Hydrocephalus and vasculitic complications may need neurosurgical input. In UK cases, travel and residence history in endemic areas such as the south-western United States, Mexico, and parts of Central and South America are often the decisive diagnostic clue.

Aspergillus CNS infection

Voriconazole is a major agent for CNS aspergillosis because of activity and CNS penetration, supported by international aspergillosis guidance. Isavuconazole may be used in selected cases, particularly where tolerability, QT interval, or interactions favour it. Surgical drainage or resection may be needed for accessible abscesses, and reversal of immunosuppression improves the chance of survival where feasible. UK laboratories increasingly consider azole resistance in Aspergillus fumigatus, so susceptibility testing is valuable.

Mucormycosis with CNS involvement

Rhino-orbital-cerebral mucormycosis is a medical and surgical emergency. Treatment usually combines urgent debridement, reversal of underlying risk factors where possible, and liposomal amphotericin B. Posaconazole or isavuconazole may be used as step-down or salvage therapy depending on response, susceptibility, tolerability, and specialist advice. Delayed surgery is associated with poor outcomes in invasive disease, so ENT, maxillofacial, ophthalmology, neurosurgery, diabetes, haematology, and intensive care input may all be needed.

Candida device-associated CNS infection

Candida meningitis or ventriculitis is most often seen in neurosurgical or device-associated settings. Treatment may include liposomal amphotericin B, sometimes with flucytosine, followed by fluconazole if the isolate is susceptible and the patient is improving. Device removal or replacement is often central to cure. Persistent positive CSF cultures should prompt review for retained infected material, abscess, or inadequate drug exposure.

Practical management issues that change outcomes

Antifungal therapy is only one part of care. Several practical decisions strongly influence outcome.

Source control is critical in device-associated Candida infection, sinus-origin mould disease, abscess, and mucormycosis. Without debridement or device removal, antifungals may fail.

Drug monitoring helps avoid under-treatment and toxicity. Flucytosine, voriconazole, posaconazole, and itraconazole often require levels, depending on local practice and patient factors.

Interactions are common. Azoles interact with calcineurin inhibitors, some anticoagulants, antiepileptics, rifamycins, antiretrovirals, chemotherapy, and many other medicines. Rifampicin can markedly reduce azole exposure, which matters when TB is in the differential.

Toxicity monitoring should be planned from day one. Amphotericin can cause renal impairment, hypokalaemia, hypomagnesaemia, and anaemia. Voriconazole can cause hepatotoxicity, neurovisual symptoms, photosensitivity, QT effects, and long-term skin toxicity. Flucytosine can cause marrow suppression and hepatotoxicity, especially with renal impairment.

Public health context is different from bacterial meningococcal disease. Most fungal meningitis cases do not require contact prophylaxis. The exception is not person-to-person spread, but recognition of outbreaks or contaminated products, which should be escalated through local infection prevention and UKHSA routes if suspected.

Severe fungal CNS infection often needs coordinated inpatient care and close monitoring.

How I would frame the first 24 hours

In a patient with suspected fungal CNS infection, the first day should answer four questions.

1. Is lumbar puncture safe, and has enough CSF been sent?

   If imaging is needed before LP, arrange it quickly. When CSF is obtained, communicate directly with microbiology.

   
   

2. Does the patient have a host factor or exposure that points to a specific fungus?

   HIV status, transplant history, neutropenia, steroids, biologics, travel, neurosurgery, and sinus symptoms are not background details. They shape the whole diagnostic pathway.

   
   

3. Is there a complication that needs urgent intervention?

   Raised intracranial pressure, hydrocephalus, abscess, infarction, orbital involvement, or necrotic sinus disease can be immediately threatening.

   
   

4. Can treatment wait for proof?

   In many cases, it cannot. Empirical therapy should be targeted to the most likely pathogen and revised as results return. The wrong antifungal can be as harmful as delayed therapy, so early specialist discussion is not optional.

   
   

Key takeaway

Fungal meningitis in the UK is uncommon, but it is not exotic. It appears in advanced HIV, transplant medicine, haematology, neurosurgery, intensive care, diabetes, and travel medicine. The diagnosis depends on suspicion, generous CSF sampling, careful exposure history, and early laboratory discussion.

The best outcomes come from treating the infection and the complications at the same time: control intracranial pressure, remove infected devices, debride invasive mould disease, monitor antifungal levels, manage interactions, and reduce immunosuppression where safe. For clinicians, the most useful habit is simple. When chronic meningitis meets immunosuppression or relevant travel, think fungal early and call microbiology before the first precious CSF sample is used up.